Molecular similarity can be defined as the theoretical explanation for sequence similarities (mainly in antigens) between two (or more) organisms. In this study, the author from India employed an integrative approach to identify antigenic sites in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) receptor binding domain (RBD) and to evaluate the molecular similarities of antigenic sites predicted in the SARS-CoV-2 S RBD with proteins/antigens from other different organisms.
The author emphasized that computational biology approaches for epitope prediction, identification, and analysis are well-developed and have been proven highly successful in predicting and identifying both weak and strong antibody epitopes.
SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus. Its genome encodes four structural proteins, namely the spike (S), envelope (E), nucleocapsid (N), and membrane (M) protein. The S protein appears to be a major pathogenic factor that contributes to the unique pathogenesis of SARS-CoV-2. The S protein is a glycosylated homotrimer with each monomer composed of subunits S1 and S2, separated by host cell proteases. The S1 domain comprises the N-terminal domain (NTD), the receptor binding domain (RBD) with a receptor binding motif (RBM), and two C-terminal domains. The RBD in the S1 subunit recognizes human angiotensin-converting enzyme 2 receptor (ACE2) and is responsible for attachment to host cells.
About the study
The author used an integrated approach that included the identification of potential antigenic sites and antigenic determinants in SARS-CoV-2 RBD based on its primary sequence and 3-dimensional structure.
Results
The SARS-CoV-2 spike RBD was found to be highly antigenic with nine potential surface antigenic sites. Seven of nine antigenic sites in the SARS-CoV-2 S protein showed molecular similarities with 54 antigenic determinants found in fifteen pathogenic bacteria, parasites, and viruses, namely in twelve pathogenic bacterial species (Mycobacterium tuberculosis, Mycobacterium leprae, Bacillus anthracis, Borrelia burgdorferi, Clostridium perfringens, Clostridium tetani, Helicobacter Pylori, Listeria monocytogenes, Staphylococcus aureus, Streptococcus pyogenes, Vibrio cholerae and Yersinia pestis), two malarial parasites (Plasmodium falciparum and Plasmodium knowlesi) and influenza virus A.
Table from the original article of Dakal TC. List of antigenic proteins from different pathogenic microorganisms and virus showing sequence similarity with predicted antigenic sites’ sequence in SARS-CoV-2 spike RBD.
S.No |
UniProt ID |
Protein Name |
Protein Description |
Organisms |
---|---|---|---|---|
1 |
O33084 |
ESXB_MYCLE |
ESAT-6-like protein EsxB |
Mycobacterium leprae (strain TN) |
2 |
P01556 |
CHTB_VIBCH |
Cholera enterotoxin subunit B |
Vibrio cholerae serotype O1 (strain ATCC 39315/El Tor Inaba N16961) |
3 |
P01558 |
ELTB_CLOPF |
Heat-labile enterotoxin B chain |
Clostridium perfringens |
4 |
P02893 |
CSP_PLAFA |
Circumsporozoite protein |
Plasmodium falciparum |
5 |
P02894 |
CSP_PLAKH |
Circumsporozoite protein |
Plasmodium knowlesi (strain H) |
6 |
P03438 |
HEMA_I000X |
Hemagglutinin |
Influenza A virus |
7 |
P03449 |
HEMA_I71A1 |
Hemagglutinin |
Influenza A virus |
8 |
P03452 |
HEMA_I34A1 |
Hemagglutinin |
Influenza A virus |
9 |
P03453 |
HEMA_177AB |
Hemagglutinin |
Influenza A virus (strain A/USSR/90/1977 H1N1) |
10 |
P03459 |
HEMA_I34A0 |
Hemagglutinin |
Influenza A virus |
11 |
P03466 |
NCAP_I34A1 |
Nucleoprotein |
Influenza A virus |
12 |
P04923 |
CRA_PLAFA |
Circumsporozoite protein-related antigen |
Plasmodium falciparum |
13 |
P04926 |
EXP1_PLAFA |
Malaria protein EXP-1 |
Plasmodium falciparum |
14 |
P04934 |
MSP1_PLAFC |
Merozoite surface protein 1 |
Plasmodium falciparum (isolate Camp/Malaysia) |
15 |
P04958 |
TETX_CLOTE |
Tetanus toxin |
Clostridium tetani |
16 |
P08089 |
M6B_STRPY |
M protein, serotype 6 |
Streptococcus pyogenes |
17 |
P09621 |
CH10_MYCTU |
10 kDa chaperonin |
Mycobacterium tuberculosis |
18 |
P09621 |
CH10_MYCTO |
10 kDa chaperonin |
Mycobacterium tuberculosis |
19 |
P0A0L2 |
ETXA_STAAU |
Enterotoxin type A |
Staphylococcus aureus |
20 |
P0A4V2 |
A85A_MYCTU |
Diacylglycerol acyltransferase |
Mycobacterium tuberculosis |
21 |
P0A4V2 |
A85A_MYCTO |
Diacylglycerol acyltransferase |
Mycobacterium tuberculosis |
22 |
P0A550 |
DPO1_MYCTU |
DNA polymerase I |
Mycobacterium tuberculosis |
23 |
P0A550 |
DPO1_MYCTO |
DNA polymerase I |
Mycobacterium tuberculosis |
24 |
P0A564 |
ESXA_MYCTU |
6 kDa early secretory antigenic target |
Mycobacterium tuberculosis |
25 |
P0A564 |
ESXA_MYCTO |
6 kDa early secretory antigenic tar |
Mycobacterium tuberculosis |
26 |
P0A5J0 |
LPQH_MYCTU |
Lipoprotein LpqH |
Mycobacterium tuberculosis |
27 |
P0A5J0 |
LPQH_MYCTO |
Lipoprotein LpqH |
Mycobacterium tuberculosis |
28 |
P0A5Q4 |
MP64_MYCTU |
Immunogenic protein MPT64 |
Mycobacterium tuberculosis |
29 |
P0A5Q4 |
MP64_MYCTO |
Immunogenic protein MPT64 |
Mycobacterium tuberculosis |
30 |
P11089 |
FLA1_BORBU |
Flagellar filament 41Â kDa core protein |
Borrelia burgdorferi |
31 |
P13423 |
PAG_BACAN |
Protective antigen |
Bacillus anthracis |
32 |
P13830 |
RESA_PLAFF |
Ring-infected erythrocyte surface antigen |
Plasmodium falciparum (isolate FC27/Papua New Guinea) |
33 |
P14013 |
OSPA_BORBU |
Outer surface protein A |
Borrelia burgdorferi |
34 |
P14013 |
OSPA_BORBN |
Outer surface protein A |
Borrelia burgdorferi |
35 |
P14013 |
OSPA_BORBZ |
Outer surface protein A |
Borrelia burgdorferi |
36 |
P14916 |
URE23_HELPY |
Urease subunit alpha |
Helicobacter pylori |
37 |
P15712 |
PSTS1_MYCTU |
Phosphate-binding protein PstS 1 |
Mycobacterium tuberculosis |
38 |
P15712 |
PSTS1_MYCTO |
Phosphate-binding protein PstS 1 |
Mycobacterium tuberculosis |
39 |
P15917 |
LEF_BACAN |
Lethal factor |
Bacillus anthracis |
40 |
P16893 |
TRAP_PLAFA |
Thrombospondin-related anonymous protein |
Plasmodium falciparum |
41 |
P19214 |
EBA1_PLAFC |
Erythrocyte-binding antigen 175 |
Plasmodium falciparum (isolate Camp/Malaysia) |
42 |
P21171 |
P60_LISMO |
Probable endopeptidase p60 |
Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679/EGD-e) |
43 |
P23024 |
TCPA_VIBCL |
Toxin coregulated pilin |
Vibrio cholera |
44 |
P24301 |
CH10_MYCLE |
10 kDa chaperonin |
Mycobacterium leprae (strain TN) |
45 |
P25893 |
|||
46 |
P26948 |
CAF1_YERPE |
F1 capsule antigen |
Yersinia pestis |
47 |
P31951 |
A85B_MYCLE |
Diacylglycerol acyltransferase |
Mycobacterium leprae (strain TN) |
48 |
P31952 |
A85B_MYCTA |
Diacylglycerol acyltransferase |
Mycobacterium tuberculosis |
49 |
P31952 |
A85B_MYCTU |
Diacylglycerol acyltransferase |
Mycobacterium tuberculosis |
50 |
P31952 |
A85B_MYCTO |
Diacylglycerol acyltransferase |
Mycobacterium tuberculosis |
51 |
Q07337 |
OSPC_BORBU |
Outer surface protein C |
Borrelia burgdorferi |
52 |
Q25893 |
Q25893_PLAFA |
Liver stage antigen-1 |
Plasmodium falciparum |
53 |
Q9U0P0 |
Q9U0P0_PLAFA |
Liver stage antigen-3 |
Plasmodium falciparum |
54 |
Q60153 |
TCPA_VIBCL |
Toxin coregulatedpilin |
Vibrio cholerae serotype O1 (strain ATCC 39315/El Tor Inaba N16961) |
Most of the antigenic determinants found in pathogenic microorganisms that showed molecular similarity to the RBD’s antigenic sites were toxins and factors with a diverse functional role in pathogens. The antigenic determinants predicted from Mycobacterium tuberculosis play a role in immune recognition escape and ensure persistence in the host body, possibly in the latent stage. 10-kDa co-chaperonin (cpn10) led in vitro to bone weakness and fragility, while the MPT64 is involved in the persistence and survival of pathogens in host cells and tissues.
The antigenic sequences predicted from malaria parasites were circumsporozoite protein-related antigen, malaria protein EXP-1, thrombospondin-related anonymous protein, liver stage antigens -1 and -3, erythrocyte-binding antigen 175, and ring-infected erythrocyte surface antigen. The circumsporozoite proteins play an important role in the invasion of liver cells in humans. The antigenic determinants predicted from Bacillus anthracis are two of the three proteins that form the anthrax toxin. Five antigenic determinants were predicted from spirochete Borrelia burgdorferi. The antigenic sequences predicted from Clostridium perfrigens and Clostridium tetani were toxin proteins, as well as the enterotoxin A from Staphylococcus aureus, M protein from Streptococcus pyogenes, and toxins from Vibrio cholerae. Two proteins predicted from Mycobacterium leprae play a role in bacterial virulence and act as chaperones to prevent membrane lysis. One predicted antigenic site in SARS-CoV-2 RBD had molecular similarity with antigenic determinant from Yersisnia pestis, a capsule-like antigen, fraction 1 (F1) which has been implicated to be involved in the ability of bacteria to prevent uptake by macrophages. Certain antigenic determinants from influenza virus A play a role in the assembly of newly budded virions.
Interestingly, a study that examined the association between the cross-reactivity to SARS-CoV-2 S protein/RBD and exposure to Plasmodium falciparum infection in 741 pre-pandemic samples from eight malaria-endemic and non-endemic countries showed that people with confirmed acute malaria had more pronounced cross-reactivity than those previously exposed to malaria but without acute Plasmodium falciparum infection. Also, IgM but not IgG cross-reactivity was higher among uninfected individuals exposed to infection in malaria-endemic areas than among people from non-endemic settings. Importantly, there was no cross-reactivity between acute Plasmodium falciparum infection and other human coronaviruses or other SARS-CoV-2 proteins. (Lapidus, S et al. Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein. Sci Rep 2022; 12, 22175.)  https://doi.org/10.1038/s41598-022-26709-7
Plasmodium falciparum
The author of the present study stated that the findings of the molecular similarities between antigenic sites in the SARS-CoV-2 RBD and antigenic determinants of fifteen pathogens (bacterial, malarial, and viral species)Â are seriously alarming because their presence makes the SARS-CoV-2 more pathogenic than any other previously known coronavirus. Especially, antigenic determinants unique to SARS-CoV-2. As all seven predicted antigenic sites in SARS-CoV-2 RBD had molecular similarity with antigenic determinants from Mycobacterium tuberculosis and Plasmodium falciparum, the author suggested that COVID-19 patients should have at least symptoms of these two diseases.
The researcher also stated that molecular similarities between antigenic determinants of the SARS-CoV-2 RBD and highly potent antigenic determinants found in fifteen pathogens might explain numerous pathophysiological complications, like exacerbated innate and adaptive immune responses leading to hyper-activation of B-cells, T-cells (both cytotoxic T-cells and T-helper cells), dendritic cells, natural killer cells, and macrophage/monocyte lineage cells, the excessive release of cytokines that adversely affect numerous vital organs and multiple organ failure.Â
The author also speculated that individuals previously infected with or immunized/vaccinated against malaria, tuberculosis (TB), or other diseases caused by fifteen microorganisms with molecular similarities between their antigenic determinants and SARS-CoV-2 RBD, are expected to display a considerable degree of resistance against SARS-CoV-2 infection. The results of a recent study that investigated the immune response in people from malaria-endemic regions of Ghana, who were exposed to Plasmodium falciparum and positive for SARS-CoV-2 has shown that modulation of immune response to SARS-CoV-2 after exposure to Plasmodium falciparum may contribute to reduced severity of COVID-19 among people living in malaria-endemic regions. https://discovermednews.com/immune-response-to-sars-cov-2-after-exposure-plasmodium-falciparum/
One possible explanation is that the memory B or T cells previously generated by these microorganisms would be reactivated upon SARS-CoV-2 infection due to similar antigenic specificity and common antigenic determinants. The authors also suggested that the over-representation of antigenic determinants from Mycobacterium tuberculosis and Plasmodium falciparum in all antigenic sites suggests that anti-malarial and anti-TB drugs can be clinically beneficial for COVID-19 treatment.Â
This article was published in Immunobiology.
Journal Reference
Dakal TC. Antigenic sites in SARS-CoV-2 spike RBD show molecular similarity with pathogenic antigenic determinants and harbors peptides for vaccine development. Immunobiology 2021 Sep; 226(5): 152091. (Open Access)Â https://www.sciencedirect.com/science/article/pii/S0171298521000395